During the pandemic, Kenda Drive-In owners Kenda and Todd Dearing found themselves in a unique position to offer more that just a night out for the the quiet community on the edge of the Ozark mountain range in Marshall, AR.

About The Series:
Before the coronavirus arrived in America, Forbes Creative Director of Video Nick Graham had committed to moving from New York to Los Angeles to establish a new video production hub. As the pandemic grew and changed life as we know it, he and his family made the difficult decision to move forward with the relocation as planned. They are driving cross-country in an RV, and documenting the stories they discover along the way. This is The Long Haul.

Episodes:
Episode 1: Brooklyn, NY: https://youtu.be/YFth0l8rfYU

Episode 2: Baltimore, MD: https://youtu.be/jLYva5j7iwM

Episode 3: Waynesboro, VA: https://youtu.be/8yzatdybVaw

Episode 4: Nashville, TN: https://youtu.be/K1JXKdXH8gY

Subscribe to FORBES: https://www.youtube.com/user/Forbes?sub_confirmation=1

Stay Connected
Forbes newsletters: https://newsletters.editorial.forbes.com
Forbes on Facebook: http://fb.com/forbes
Forbes Video on Twitter: http://www.twitter.com/forbes
Forbes Video on Instagram: http://instagram.com/forbes
More From Forbes: http://forbes.com

Forbes covers the intersection of entrepreneurship, wealth, technology, business and lifestyle with a focus on people and success.

On the first Monday of May, Pfizer dosed the initial batch of healthy American volunteers in Baltimore with an experimental Covid-19 vaccine it developed with Germany’s Bio-NTech. Bourla was informed immediately. The following day, in an interview from his home in suburban Scarsdale, New York, he pointed out that it normally takes years to accomplish what Pfizer had just done in weeks. “How fast we moved is not something you could expect from the big, powerful pharma,” he said. “This is speed that you would envy in an entrepreneurial founder-based biotech.”

A Greek veterinarian who worked his way up the Pfizer corporate ladder for 25 years before becoming CEO in 2019, Bourla says nothing in his career could have prepared him for this moment. But he does believe the massive corporate transformation he has led—steering a behemoth conglomerate (2019 sales: $51.8 billion) deeper into the high-risk, high-reward game of developing new patented medicines and away from generic drugs and consumer products like Advil and Chapstick—has prepared Pfizer.

For Bourla, 58, the last four months have been a rollercoaster, an unending series of setbacks and victories. Pfizer is not alone in the race. Most of the world’s biggest pharmaceutical companies, including Johnson & Johnson, Sanofi, AstraZeneca and Roche, are throwing everything they can at Covid-19.

Some experts feel Bourla’s timeline—a viable vaccine in a matter of a few months—is simply unrealistic. Undeterred, Bourla has tasked hundreds of researchers to scour Pfizer’s trove of experimental and existing medicines to look for potential therapies. Early on, he openly authorized having discussions and sharing proprietary information with rival firms, moves unheard of in the secretive world of big pharma. Bourla has made Pfizer’s manufacturing capabilities available to small biotech concerns and is in talks as well to make large quantities of other companies’ Covid-19 drug candidates.

Pfizer’s most prominent effort is its work with Mainz, Germany–based BioNTech, an innovative $120 million (2019 sales) outfit that is mostly known for making cancer medications. The resulting experimental Covid-19 vaccine works with messenger RNA, a bleeding-edge technology that has never resulted in a successful treatment. Pfizer is hoping to get emergency-use authorization from the U.S. government for the vaccine by October. Its unique strategy is to rapidly pit four different mRNA vaccine candidates against one another and double down on the most likely winner.

Read the full profile on Forbes: https://www.forbes.com/sites/nathanvardi/2020/05/20/the-man-betting-1-billion-that-pfizer-can-deliver-a-vaccine-by-this-fall/#69185f30382e

Subscribe to FORBES: https://www.youtube.com/user/Forbes?sub_confirmation=1

Stay Connected
Forbes newsletters: https://newsletters.editorial.forbes.com
Forbes on Facebook: http://fb.com/forbes
Forbes Video on Twitter: http://www.twitter.com/forbes
Forbes Video on Instagram: http://instagram.com/forbes
More From Forbes: http://forbes.com

Forbes covers the intersection of entrepreneurship, wealth, technology, business and lifestyle with a focus on people and success.

A new workplace survey by Engine Insights for Smartsheet reveals that working from home as a result of COVID-19 is difficult for all workers, but none more than Generation-Z and Millennials. In fact, despite being digital natives, fully 95% of Gen-Z workers and 93% of Millennial workers admit they’re having a tough time with the transition to working remotely.

Three-fourths of the U.S. workforce feels less connected than they did before the COVID-19 pandemic, reports Smartsheet, with notably higher numbers for Gen-Z (82%) and Millennials (81%). Moreover, since they started working from home, 60% of American workers feel less informed about what’s going on within their company. But, here again, younger workers reflect higher numbers, with 74% of Gen-Zers and 66% of Millennials, compared to just 53% and 50% of Gen-Xers and Boomers, respectively.

Read the full profile on Forbes: https://www.forbes.com/sites/markcperna/2020/05/11/working-from-home-is-tougher-than-we-thought/#12cd1c481e78

For more from Mark C. Perna, visit https://www.markcperna.com or @MarkPerna

Subscribe to FORBES: https://www.youtube.com/user/Forbes?sub_confirmation=1

Stay Connected
Forbes newsletters: https://newsletters.editorial.forbes.com
Forbes on Facebook: http://fb.com/forbes
Forbes Video on Twitter: http://www.twitter.com/forbes
Forbes Video on Instagram: http://instagram.com/forbes
More From Forbes: http://forbes.com

Forbes covers the intersection of entrepreneurship, wealth, technology, business and lifestyle with a focus on people and success.